Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX

Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX | bioRxiv /* */ /* */ <!-- <!-- /*! * yepnope1.5.4 * (c) WTFPL, GPLv2 */ (function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-M677548'); Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX Delphine Autheman , Cristina Viola , Georgina Rhodes , Simon Clare , Cordelia Brandt , Katherine Harcourt , View ORCID Profile Gavin J. Wright doi: https://doi.org/10.1101/2025.07.08.663690 Delphine Autheman 1 Cell Surface Signalling Laboratory, Department of Biology, Hull York Medical School , University of York, York, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cristina Viola 1 Cell Surface Signalling Laboratory, Department of Biology, Hull York Medical School , University of York, York, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site Georgina Rhodes 1 Cell Surface Signalling Laboratory, Department of Biology, Hull York Medical School , University of York, York, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site Simon Clare 2 Wellcome Sanger Institute , Hinxton, UK 3 Department of Medicine, University of Cambridge , Cambridge, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cordelia Brandt 2 Wellcome Sanger Institute , Hinxton, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site Katherine Harcourt 2 Wellcome Sanger Institute , Hinxton, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site Gavin J. Wright 1 Cell Surface Signalling Laboratory, Department of Biology, Hull York Medical School , University of York, York, UK 4 York Biomedical Research Institute, University of York , York, UK Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Gavin J. Wright For correspondence: gavin.wright{at}york.ac.uk Abstract Full Text Info/History Metrics Preview PDF Abstract Animal African trypanosomiasis (AAT) is an infectious wasting disease of economically important livestock caused by Trypanosoma spp. parasites. The disease is primarily caused by two species: T. congolense and T. vivax which are endemic in many African countries. AAT is managed by therapeutic and prophylactic drugs; however, resistance is now widely reported and the development of new drugs has been impeded due to a chronic lack of investment. Recently, we identified an invariant flagellar-associated cell surface protein (IFX) that could elicit protective immune responses when used as a vaccine against T. vivax . We showed that a complement-recruiting anti-IFX monoclonal antibody can prevent infection when used prophylactically. Here, we show that this same unmodified antibody can be used to cure T. vivax infections in a murine experimental model. Importantly, we show that infections can be treated with a single dose and demonstrate full cure by the lack of detectable parasites in peripheral tissues even after immunosuppression. Using structural modelling and site-directed mutagenesis, we localise the protective antibody epitope thereby identifying targetable regions on IFX to improve vaccine design. Together, these findings validate IFX as both a prophylactic and curative drug target that could be useful in the management of AAT. Importance Trypanosoma vivax is a parasite that causes animal African trypanosomiasis (AAT), a chronic wasting disease that infects economically-important livestock animals which is a particular problem in African countries south of the Sahara. The impact of this disease is significant: it is responsible for over 3 million cattle deaths and an estimated $4.5 billion of annual lost productivity. There is a desperate need to develop new control measures because resistance is now widely reported to the drugs commonly used to treat this infection. We show here that a single dose of an unmodified monoclonal antibody that recognises IFX - a parasite cell surface protein localised to the flagellum - is sufficient to cure an established T. vivax infection with no parasite reservoirs detectable in peripheral tissues. Our finding validates IFX as a new drug target and provides a rationale route to the development of new drugs to target AAT. Introduction The livelihoods of millions of people living in Africa are at risk due to infectious diseases that affect the health of their livestock which provide them with essential food, milk, clothing, manure and draught power. One major livestock disease is animal African trypanosomiasis (AAT) which is caused by blood-dwelling parasites of the genus Trypanosoma that affect many important farm animals including sheep, pigs, and especially cattle ( 1 ). The impact of this disease is significant: over 3 million cattle die from this disease annually with a direct economic cost to the African economy amounting to many hundreds of millions of dollars ( 2 ). This disease therefore represents a major constraint on the economic development of the mainly agrarian societies in African countries south of the Sahara ( 3 , 4 ). Although several species of trypanosome parasite can cause this disease in animals, the two most prevalent are T. congolense and T. vivax . The disease is currently managed by controlling the tsetse fly vector population and the use of trypanocidal drugs ( 5 ). The most commonly used drugs for therapy and prophylaxis are diminazene aceturate and isometamidium chloride: both were developed over seventy years ago in the 1950s ( 6 , 7 ). These drugs can cause toxic side effects and when inappropriately administered, for example by underdosing, has led to the emergence of drug resistance which has now been reported in 21 out of the 37 countries in which the disease is endemic ( 8 ). The development of new trypanocides for livestock has lacked sufficient investment because there is a poor economic case: new drugs remain expensive to develop, and a price point that would provide a satisfactory return for developers could not be met by the primary customers who are largely subsistence farmers. Despite this, there has been some encouraging recent progress achieved by the repurposing of drugs developed to treat human African trypanosomiasis ( 9 – 11 ). Another control tool would be the development of an effective vaccine, but none yet exist for AAT ( 12 ). Vaccination has generally been considered a low value option for this disease because the parasite has evolved sophisticated immunoregulatory mechanisms such as antigenic variation ( 13 ), the ability to rapidly clear surface bound host antibodies ( 14 ), and disruption of B-cell development and maintenance ( 15 , 16 ) all of which enable trypanosomes to thrive in the blood of their infected host. We have previously shown that it is possible to induce protective immunity in an experimental model of T. vivax infection by eliciting an antibody response to an invariant flagellum-associated antigen called IFX prior to challenge by the parasite ( 17 ). In our experiments to determine the immunological mechanisms of protection, we identified a small panel of monoclonal antibodies, some of which could confer protection to T. vivax infection by passive transfer. While the original hybridoma-derived IgG1-isotype antibodies conferred only modest protection, reformatting the isotype of one antibody called 8E12 as an immune-effector-recruiting IgG2a isotype could elicit very potent protection when delivered prophylactically. We additionally demonstrated that by mutating the C1q and FcR binding sites in the Fc region of the antibody, we showed that complement recruitment was the major protective mechanism followed by FcR binding, and lastly direct opsonization of the IFX antigen ( 17 ). The passive transfer of immune serum from convalescent patients to treat and prevent infectious diseases has a long history of success ( 18 ). This approach, however, poses challenges in the clinic because it requires a sufficiently large number of donors, often varies in its efficacy, and carries the risk of unintentionally transferring infections. Success in treating a range of diseases from cancer to autoimmune disease using monoclonal antibody therapeutics has driven biotechnological progress that have made the isolation and large-scale production of antibody-based drugs rapid and cost effective ( 19 ). Increasingly, this class of drugs has been developed for the treatment and prevention of infectious diseases ( 20 ). For example, several antibody-based drugs targeting the SARS-CoV-2 spike protein were developed within a few months during the COVID-19 pandemic including bamlanivimab, sotrovimab, and regdanvimab ( 21 , 22 ). A major advantage of these drugs are their long pharmacokinetics, lack of toxicity, and generalised production methods ( 23 ). As well as treating viral infections, this strategy has also been shown to work as both therapy and prophylaxis for bacterial infections ( 22 , 24 ). Importantly, antibody-based therapies have also been used to treat and prevent parasitic infections. This includes antibodies that target the circumsporozoite protein of sporozoite-stage Plasmodium falciparum parasites which showed dose-dependent prevention of infection in Malian patients over a period of six months ( 25 , 26 ). Similarly, experimental Trypanosoma brucei infections could be cured with a single dose of an antibody-drug conjugate targeting the haptoglobin-haemoglobin receptor ( 27 ). Here, we investigate the possibility of using a monoclonal antibody targeting the T. vivax vaccine antigen IFX in a drug-like manner. We use structural modelling to identify the epitope of the 8E12 antibody and show using a murine infection model that a single dose of the unmodified antibody can cure an established T. vivax infection. Results Structural modelling identified the location of the 8E12 epitope on IFX To explore the possibility of using the IFX protein as a potential drug target, we first characterised the anti-IFX 8E12 monoclonal antibody that could elicit passive protection to T. vivax infections in more detail. We sequenced the rearranged light and heavy chains of the 8E12 antibody which had been amplified from a hybridoma to create a single plasmid ( 28 ). Sequencing of this plasmid revealed kappa light chain usage and identified the amino acids forming the antibody paratope ( Supplementary Figure 1 ). In our original study, we determined the 8E12 binding affinity as only moderate ( K D =14nM), and mapped the 8E12 epitope to the N-terminal 168 amino acids of IFX by expressing fragments of the IFX ectodomain ( 17 ). To characterize the 8E12 epitope further, we first asked if the epitope was conformational by denaturing the IFX protein by heat treatment and reduction. We observed that while some of the binding activity was lost upon both heat treatment and protein reduction, not all binding activity was lost indicating that the 8E12 epitope was at least partially dependent on protein folding ( Fig. 1a ). There is no experimental structural information on IFX, but recent advances in protein structure ( 29 ) and binding interface prediction ( 30 ) presented the opportunity to model both the IFX structure and predict the 8E12 epitope. Structural modelling suggests that the extracellular region of IFX adopts a dumbbell shape composed of two groups of alpha-helices joined by a long central helix ( Fig. 1b ). By using the sequence of IFX and the light and heavy chains of the 8E12 antibody, we used Alphafold3 to predict the location of possible epitopes. Of the five most highly-ranked models, all converged on a region of IFX at the tip of one of the helical clusters ( Fig. 1b ). We were reassured by the convergence of these predictions with the experimentally known N-terminal location of the epitope, and the lack of overt steric clashes with the location of N-linked glycans. Download figure Open in new tab Figure 1. Identifying the location of the anti-IFX 8E12 monoclonal antibody epitope by structural modelling and site-directed mutagenesis. (a) Biochemical characterisation of anti-IFX monoclonal antibody epitopes. The monobiotinylated IFX ectodomain was immobilised in wells of a streptavidin-coated microtitre plate without treatment or after heat treatment with reduction. Immunoreactivity of antibodies 3D12, 6B3 and 8C9 was completely abrogated in the denatured protein showing they recognised a conformational epitope; immunoreactivity to 2H3 and 10E2 was retained upon denaturation demonstrating these antibodies recognized a non-conformational epitope. Immunoreactivity to 8E12 was only partly ablated by heat treatment and protein reduction demonstrating the epitope was only partly conformational. Bars represent means ± SD n = 3. (b) Structural model of the IFX-8E12 Fab complex. The predicted structure of the extracellular region of IFX (green), including the location of modelled potential N-linked glycans (gray sticks) in complex with the 8E12 antibody Fab fragment showing light chain (red) and heavy chain (blue). Inset: atomic details of the 8E12 epitope highlighting the position of glutamic acid residues at positions 154 and 157. The approximate location of the parasite plasma membrane phospholipids are shown in gray. (c) Identification of the epitope recognised by the 8E12 antibody. The entire extracellular region of IFX was expressed as either its wild-type form (left panel) or the E154K / E157K mutant (right panel) as a soluble biotinylated protein and immobilised in wells of a streptavidin-coated plate. Titrations of the indicated anti-IFX antibodies were tested for direct binding to the IFX proteins by ELISA. While both wild-type and mutant IFX bound antibodies 3D12, 6B3 and 8C9, the 8E12 antibody bound only the wild-type form. To experimentally validate these predictions, we identified two solvent-exposed glutamic acid residues (E154 and E157 of TvY486_0807240) which contributed hydrogen bonds in the 8E12 co-complex structure prediction and mutated these to lysine. We showed that E154 and E157 contributed to the 8E12 epitope by showing that the mutant IFX protein was unable to bind the 8E12 antibody ( Fig. 1c ). Importantly, the mutant IFX retained the ability to bind other anti-IFX monoclonal antibodies demonstrating the mutations did not cause significant mis-folding of the IFX ectodomain ( Fig. 1c ). Together, these data identify the 8E12 epitope to a membrane-distal tip of a helical cluster on the IFX ectodomain. Repeated doses of 8E12 mAb can cure an experimental T. vivax infection In our initial experiments, 8E12 was used prophylactically to prevent infection by administering the 8E12 antibody the day before, on the day, and the day after infection with T. vivax ( 17 ). To be used in a drug-like manner, the antibody must be able to clear an established infection. First, a bulk preparation of the 8E12 monoclonal antibody was produced by transfecting HEK293 cells and purified using immobilised protein G. The antibody was shown to be highly active by quantifying binding to recombinant IFX by ELISA and over 95% pure by resolving the preparation on a protein gel ( Supplementary Figure 2 ). Next, we infected mice with a transgenic form of T. vivax constitutively expressing the firefly luciferase, and waited until four days post infection where a patent infection was apparent, and could be quantified using bioluminescent imaging. At day five postinfection, the average bioluminescence was 4.1×10 7 photon s -1 which corresponds to a parasitaemia of ∼1×10 6 parasites per mL of blood, a value that is towards the highest amount detected in infected cattle ( 31 ). From day five, we administered a total of three daily doses of 50, 100, 200, or 400 micrograms of purified 8E12 IgG2a-formatted antibody and continued to measure parasitaemia each day ( Fig. 2a ). We observed that the lowest (50μg) doses, while slowing the multiplication of the parasite, was not able to clear the infection and all five animals were removed from the study by day nine ( Fig. 2b, c ). While 100μg doses could reduce parasitemia in most animals to very low levels by day eight, there was a recrudescence of the infection in each animal such that all had to be removed from the study by day 15 ( Fig. 2b, c ). At 200μg, parasites were reduced below the limits of detection by day seven ( Fig. 2b ), but then showed recrudescence of this infection that was highly variable between individuals. Interestingly, two of the five treated animals showed the ability to control the infection after day 20 which significantly exceeds the measured in vivo half life for an IgG2a-isotype antibody which has been measured at 6 to 8 days ( 32 ) suggesting that the animals had acquired some immunity. All animals receiving 400μg doses showed no evidence of recrudescence with no detectable parasites from day seven until beyond day 60. Download figure Open in new tab Figure 2. Cure of an experimental T. vivax infection with the anti-IFX 8E12-IgG2a-formatted monoclonal antibody. ( a ) Schematic showing the experimental plan. Groups of five animals were infected with luciferase-expressing transgenic T. vivax parasites on day 0. Varying doses of the 8E12 monoclonal antibody were administered daily on days 5, 6, and 7 and parasitaemia was quantified by bioluminescent imaging. Animals were immunosuppressed by two doses of cyclophosphamide (CPM). ( b ) Images of mice infected with bioluminescent T. vivax immediately before and 24 hours after the last administration of the indicated doses of the 8E12 antibody. ( c ) Longitudinal analysis of individual infected animals with the indicated doses of 8E12 relative to an isotype-matched control antibody (Ctrl). Bioluminescence (solid lines) and survival (dashed lines) are plotted for each experimental group. Background level of bioluminescence is indicated by grey shading. Crosses indicate where animals were removed from the study for welfare reasons that are thought to be unrelated to the infection. Black and grey arrows represent doses of 8E12 antibody and injection of the cyclophosphamide immunosuppressant respectively. Hash symbols represent potential bioluminescence signal leakage from a heavily infected mouse to an adjacent mouse with a lower bioluminescence signal during image acquisition. ( d ) Lack of residual parasites in peripheral tissues of treated and immunosuppressed animals. No bioluminescent parasites were detected in the named tissues of a T. vivax -infected mouse that was administered with three 200μg doses of the 8E12 antibody and subsequently treated with an immunosuppressant (left panels), relative to a control infected animal (right panels). It is known that trypanosomes can reside in peripheral tissues such as the brain and adipose tissue which may have limited accessibility to antibody-based drugs. To ensure that there were no residual parasites that were being suppressed by the acquisition of immunity during the course of the experiment, we immunosuppressed apparently cured animals with two doses of cyclophosphamide at days 61 and 64, and observed the animals for a further fifteen days. In no case did we observe any recrudescent infections. To further ensure that no parasite reservoirs remained, we dissected out tissues of cured and immunosuppressed mice and subjected them to sensitive in vivo imaging. Again, we observed no parasite reservoirs in cured animals ( Fig. 2d ). Cure of an experimental T. vivax infection with a single dose of 8E12 antibody Cattle are the main target species for drugs that treat animal African trypanosomiasis and because they usually are left to roam freely around the bush and handling facilities are often rudimentary, being able to treat the disease with a single dose would be a major advantage. To determine whether animals could be cured by a single dose, we again infected groups of mice with T. vivax before administering a single dose of either 300, 400 or 600μg of the 8E12-IgG2a-formatted antibody ( Fig. 3a ). To determine how rapidly parasites were killed, we imaged all animals at 4 and 24 hours after the time of treatment. Consistent with our earlier finding that complement plays the major role in the protective immunological mechanism ( 17 ), we observed a dramatic reduction in parasitaemia at four hours which progressed to below the limit of detection by 24 hours ( Fig. 3a, b ). There was a recrudescence of the infection in all animals receiving the 300μg dose such that all animals were removed from the study by day 14. Two out of the five animals receiving the 400μg dose were apparently cured of the infection, and a further two animals showed a drastic reduction in parasitaemia by day 14 suggesting acquisition of adaptive immunity ( Fig. 3a ). All animals receiving a single 600μg dose were apparently sterilely cured. To demonstrate that there were no remaining parasites below the limits of detection, we immunosuppressed animals on day 48, and showed no recrudescence of the infection. Again, we dissected tissues of remaining immunosuppressed animals on day 57 and showed no evidence of residual parasites in peripheral tissues ( Fig. 3c ). Download figure Open in new tab Figure 3. Rapid cure of an experimental T. vivax infection with a single dose of anti-IFX 8E12-IgG2a-formatted monoclonal antibody. ( a ) Longitudinal analysis of individual infected animals with the indicated single doses of 8E12 relative to an isotype-matched control antibody (Ctrl). Bioluminescence (solid lines) and survival (dashed lines) are plotted for each experimental group. Background level of bioluminescence is indicated by grey shading. Crosses indicate where animals were removed from the study for welfare reasons thought to be unrelated to the infection. Black and grey arrows represent the single dose of 8E12 antibody and injection of cyclophosphamide (CPM) immunosuppressant respectively. Hash symbols represent potential bioluminescence signal leakage from a heavily infected mouse to an adjacent mouse with a lower bioluminescence signal during image acquisition. ( b ) Dorsal views of mice infected with bioluminescent T. vivax at 0 (Dpi 5), 4 (Dpi 5 - 4h) and 24 (Dpi 6) hours after the administration of the indicated doses of the 8E12 antibody showing rapid cure of infection. ( c ) Lack of residual parasites in peripheral tissues of treated and immunosuppressed animals. No bioluminescent parasites were detected in the named tissues of a T. vivax -infected mouse that was administered with a single 400μg dose of the 8E12 antibody and subsequently treated with an immunosuppressant (left panels), relative to a control infected animal (right panels). Discussion Here we have demonstrated that a single dose of a purified but otherwise unmodified monoclonal antibody can cure an established parasitic infection. This leads to the wider question of whether this general strategy of using antibody-based drugs could be a realistic treatment option for parasitic diseases of livestock. It is well known that the passive transfer of polyclonal immune serum from convalescent patients or immunised animals can be an effective treatment for infectious diseases and neutralising toxins in humans ( 33 – 35 ). This approach is unlikely to be a practical option for an endemic disease of livestock because with an estimated 350 million heads of cattle in Africa, this number is impractically large ( 36 ). The general view is that therapeutic monoclonal antibodies are too expensive for use in livestock, but recent technological developments in isolating and producing large amounts of monoclonal antibodies driven by the multi-billion dollar therapeutic antibody industry has made these drugs much more affordable. The adoption of generalised production methods and economies of scale mean that gram quantities of purified antibody can be produced for as little as $10 ( 37 ), and it is likely that these costs will continue to decrease. These factors have spurred the use of therapeutic antibodies to treat infectious diseases either by targeting susceptible pathogen proteins or even host proteins ( 38 – 40 ). Clearly, there would be some challenges for the use of such a strategy for the treatment of AAT. Firstly, this disease is endemic in developing countries where a reliable cold chain to ensure the protein-based product retains activity cannot be assumed. Advances in the design of heat-stable affinity scaffolds, however, provide confidence that this problem could be overcome ( 41 , 42 ). Also, antibody accessible cell surface proteins are often polymorphic so that specific antibody-based reagents will almost certainly be species-specific meaning that a single drug would be unlikely to be effective against different species of trypanosome. IFX, for example, is only found in T. vivax with no easily identifiable orthologues in other sequenced species ( 17 ). Because T. congolense and T. vivax are co-endemic in Africa, this would require the development of two different drugs, although a drug targeting just T. vivax would be useful in regions such as South America which has a large cattle industry and where T. vivax is the primary cause of AAT. Administration of antibody doses that were not sufficient for cure typically resulted in a rapid reduction in parasitaemia but that resulted in later recrudescence of the infection. In some animals, these later waves of parasitaemia could be controlled, even more than two weeks after the last antibody dose. This suggests that the adaptive immune system had a role in controlling the infection at this stage because the half life of circulating antibodies is typically around a week in mice. This may suggest that T. vivax infections do not significantly disable the adaptive immune system in the way that has been reported for T. brucei infections in mice ( 16 , 43 ). Targeting infectious diseases with antibody-based drugs does have some advantages. The antibody described here can be used in both a curative and prophylactic manner. This would be important for cattle farmers in Africa who generally lack adequate animal holding facilities and so a single dose drug that would cure current infections and provide lasting protection would be valuable and more practical to administer. Antibodies have excellent pharmacokinetics with circulating half-lives of several weeks due to their relatively large size and active recycling mechanisms mediated by the neonatal Fc receptor (FcRn) ( 44 ). Engineering of the antibody constant regions that interact with FcRn have enabled circulating half lives to be significantly extended ( 45 , 46 ). For use in cattle, it would be important to bovinise the antibody so that it effectively recruits immune effectors and does not elicit host anti-drug immune responses. The recent sequencing, annotation, and functional characterisation of the bovine antibody locus now provides the necessary information to achieve this ( 47 ). Motivated by the use of antibody-drug conjugates (ADCs) that have been used to treat cancer, research from MacGregor and colleagues showed that an experimental T. brucei infection could be cured with a single dose of an antibody targeting the haptoglobin-haemoglobin receptor conjugated to the toxin pyrrolobenzodiazepine ( 27 ). While initially conceived as a curative drug for human use, a similar ADCs strategy could increase the potency of similar drugs for use in livestock. Here though, there may be a conflict between trying to increase the in vivo half-life of the drug to provide prophylactic cover, and the need to ensure there is no long-lasting drug toxicity remaining in livestock products such as the milk and meat which would be undesirable for consumers. In summary, the work described here lends further support for the use of antibody-based drugs to treat livestock infectious diseases and identifies IFX as a new curative and preventative drug target for animal African trypanosomiasis. Materials and Methods Mouse strains and ethical approvals All mouse experiments were performed under UK Home Office governmental regulations (project licence numbers PD3DA8D1F and P98FFE489) and European directive 2010/63/EU. Research was ethically approved by the Sanger Institute Animal Welfare and Ethical Review Board. Mice were maintained under a 12-h light/dark cycle at a temperature of 19–24 °C and humidity between 40 and 65%. The mice used in this study were 6–14-week-old female Mus musculus strain BALB/c, which were obtained from a breeding colony at the Research Support Facility, Wellcome Sanger Institute. Statistical analysis The experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment, although animal dosing and parasite quantification were performed by independent researchers. Cell lines and antibodies Recombinant proteins and antibodies used in this study were expressed in HEK293-6E cells provided by Y. Durocher. Cell lines were not authenticated but were tested for mycoplasma. The 8E12 antibody was cloned and expressed recombinantly as a mouse IgG2a isotype as described ( 17 , 28 ). The mouse IgG2a isotype control antibody was C1.18.4, BioXcell Cat. No. BE0085. The other anti-IFX antibodies, 3D12, 6B3, 8C9, 10E2 and 2H3 were produced and purified by hybridoma supernatant as described ( 17 ). The antibody used for protein quantification in ELISAs was a mouse monoclonal anti-His (His-Tag monoclonal antibody, 70796, EMD-Millipore). The secondary antibody used was a goat anti-mouse alkaline phosphatase conjugated secondary (A3562, Sigma-Aldrich). Recombinant protein and antibody expression and purification The recombinant soluble IFX ectodomain and controls were expressed in HEK293-6E cells as described ( 17 ). The IFX E154K/E157K mutant was produced using gene synthesis by Twist Biosciences. Proteins were expressed as enzymatically monobiotinylated proteins by co-transfection with a secreted version of the protein biotin ligase (BirA) as previously described ( Kerr et al. 2012 ). Supernatants were collected five days after transfection, filtered and stored at 4°C until use. Proteins were purified using Ni 2+ immobilized metal-ion affinity chromatography as described ( 48 ). ELISAs To determine if the anti-IFX antibodies recognised a conformational epitope, the purified monobiotinylated ectodomain of IFX was denatured by heat treatment (90°C) in the presence of 10 millimoles of DTT for 10 minutes; once cooled 20 millimoles of iodoacetamide was added. The immunoreactivity of the 8E12 monoclonal antibody to the entire ectodomain of wild type IFX and the E154K/E157K mutant was quantified by ELISA. Purified ectodomains were normalised by dilution in PBS containing 0.2% Tween-20 (PBST) and 2% BSA and captured on a streptavidin-coated microtitre plate by incubating overnight at 4°C. Plates were washed two times with PBST, and once with PBS. Purified anti-IFX monoclonal antibodies were diluted in PBS/2% BSA, added to the ELISA plate and incubated overnight at 4°C. A 1 in 1000 dilution of an anti-6His antibody (EMD millipore) was used as a control to ensure ectodomains were captured. The plate was washed two times with PBST, and once with PBS, before incubating for one hour with a 1 in 5000 dilution of anti-mouse IgG secondary antibody conjugated to alkaline phosphatase (Sigma-Aldrich). After two further washes with PBST, and one wash with PBS, 70 μL of 1 mg/mL Sigma 104 phosphatase substrate was added, and substrate hydrolysis quantified at 405 nm using a plate reader (Spark, Tecan). Structural modelling The three amino acid sequences encoding the light and heavy chains of the 8E12 Fab region and entire ectodomain of IFX (Uniprot: G0TZT9) were used as an input for AlphaFold3 for structural modeling. Models that exceeded the template modeling (pTM) and interface predicted template modeling (ipTM) scores of 0.5 and 0.8 respectively, and with the highest ranking predicted ‘Local Distance Difference Test’ pLDDT scores were selected for residue mutation. Quantification of T. vivax infections by bioluminescent in vivo imaging Mice were infected with bloodstream forms of T. vivax parasites from the blood of an infected donor mouse at the peak of parasitaemia. Parasites were diluted in PBS and 20 mM D-glucose, quantified by microscopy, and used to infect mice by intravenous injection. The luciferase substrate D-luciferin (potassium salt, Source BioScience) was resuspended to 30 mg mL −1 in Dulbecco’s PBS (Hyclone), filter-sterilized (0.22 μm), and stored in aliquots until use at −20 °C. Luciferin was administered by intraperitoneal injection at 200 mg kg −1 ten minutes prior to imaging. Mice moved freely for three minutes before being anaesthetized (2.5% isoflurane) and placed in the imaging chamber where anaesthesia was maintained. The average background bioluminescence measurement was determined by luciferin administration in five uninfected female BALB/c mice and calculating the mean whole-body bioluminescence. This background value is indicated as a light grey shading on bioluminescence plots where appropriate. Long-term persistence of the parasites in different organs of infected mice was determined by imaging mice which were then euthanized with an overdose of anaesthetic. Mice were perfused with PBS until the perfusion fluid ran clear, the organs were dissected, and arranged on a Petri dish and bathed in PBS containing 20 mM glucose and 3.3 mg mL −1 luciferin. Emitted photons were acquired by a charge coupled device (CCD) camera (IVIS Spectrum Imaging System, Perkin Elmer). Regions of interest (ROIs) were drawn and total photons emitted from the image of each mouse were quantified using Living Image software version 4.7.4 (Xenogen), the results were expressed as the number of photons s −1 . Bioluminescence values were exported and plotted in Prism GraphPad version 8.0.2, which was also used for testing statistical significance where needed. Persistence of potential parasite reservoirs in 8E12-IgG2a treated mice was assessed by immunosuppression. Mice received two doses of cyclophosphamide (150mg/kg, Cayman Chemical) three days apart using intraperitoneal injections and were monitored by imaging to assess parasite recrudescence. Supplementary Figures Download figure Open in new tab Supplementary Figure 1. The protein sequences of the anti-IFX 8E12 monoclonal antibody light and heavy chains. Secretion signal peptides are shown in bold, and antibody constant regions in italics. The closest sequence similarity matching to mouse V and J region gene segments were: light chain Igkv3-2*01 and Igkj2*01 ; heavy chain Ighv6-6*01 and Ighj3*01 . Complementarity determining regions in both antibodies are underlined. Download figure Open in new tab Supplementary Figure 2. Preparation of a pure and active preparation of the 8E12-IgG2a-formatted monoclonal antibody. HEK293-6E cells were transfected with a single plasmid encoding both light and heavy chains of the 8E12 monoclonal antibody and the expressed antibody purified using protein G resin. ( a ) One microgram of purified antibody was resolved on an SDS-PAGE gel under reducing conditions and shown to be over 95% pure. ( b ) Purified 8E12 antibody is highly active. Purified 8E12 antibody was serially diluted and tested for binding activity to the entire ectodomain of IFX expressed as a soluble enzymatically monobiotinylated recombinant protein captured on a streptavidin-coated microtitre plate; the ectodomain of human CD200 was used a negative control. Data points represent means ± SD; n =4. Acknowledgements This research was funded by the Wellcome Trust (grant 206194) and the Gates Foundation (INV-005870). We thank Sanger Institute animal technicians for their support and Craig Mackenzie and Ben Luisi for preliminary work on anti-IFX monoclonal antibodies. References (1). ↵ Okello I , Mafie E , Eastwood G , Nzalawahe J , Mboera LEG . 2022 . African Animal Trypanosomiasis: A Systematic Review on Prevalence, Risk Factors and Drug Resistance in Sub-Saharan Africa . J Med Entomol doi: 10.1093/jme/tjac018 . OpenUrl CrossRef PubMed (2). ↵ Kristjanson PM , Swallow BM , Rowlands GJ , Kruska RL , de Leeuw PN . 1999 . Measuring the costs of African animal trypanosomosis, the potential benefits of control and returns to research . Agric Syst 59 : 79 – 98 . OpenUrl CrossRef Web of Science (3). ↵ Shaw APM . 2009 . Assessing the economics of animal trypanosomosis in Africa--history and current perspectives . Onderstepoort J Vet Res 76 : 27 – 32 . OpenUrl PubMed (4). ↵ Morrison LJ , Barrett MP , Steketee PC , Cecchi G , Kijanga O , Mramba F , Auty HK . 2024 . What is needed to achieve effective and sustainable control of African animal trypanosomosis? Trends Parasitol 40 : 679 – 686 . OpenUrl PubMed (5). ↵ Diall O , Cecchi G , Wanda G , Argilés-Herrero R , Vreysen MJB , Cattoli G , Viljoen GJ , Mattioli R , Bouyer J. 2017 . Developing a progressive control pathway for African animal trypanosomosis . Trends Parasitol 33 : 499 – 509 . OpenUrl CrossRef PubMed (6). ↵ Watkins TI , Woolfe G. 1952 . Effect of changing the quaternizing group on the trypanocidal activity of dimidium bromide . Nature 169 : 506 – 507 . OpenUrl PubMed (7). ↵ Jensch H. 1955 . 4, 4’-Diamidino-diazoaminobenzene, a new agent in the treatment of trypanosomiasis and babesiasis . Arzneimittelforschung 5 : 634 – 635 . OpenUrl PubMed (8). ↵ Ungogo MA , de Koning HP . 2024 . Drug resistance in animal trypanosomiases: Epidemiology, mechanisms and control strategies . Int J Parasitol Drugs Drug Resist 25 : 100533 . OpenUrl PubMed (9). ↵ Ilbeigi K , Mabille D , Matheeussen A , Hendrickx R , Claes M , Van Reet N , Anthonissen R , Hulpia F , Lin C , Maes L , Regnault C , Whitfield P , Roy R , Ungogo MA , Sterckx YG-J , De Winter H , Mertens B , Bundschuh M , De Koning HP , Van Calenbergh S , Caljon G. 2025 . Discovery and development of an advanced lead for the treatment of African trypanosomiasis . ACS Infect Dis 11 : 131 – 143 . OpenUrl PubMed (10). Smith A , Wall RJ , Patterson S , Rowan T , Rico Vidal E , Stojanovski L , Huggett M , Hampton SE , Thomas MG , Corpas Lopez V , Gillingwater K , Duke J , Napier G , Peter R , Vitouley HS , Harrison JR , Milne R , Jeacock L , Baker N , Davis SH , Simeons F , Riley J , Horn D , Brun R , Zuccotto F , Witty MJ , Wyllie S , Read KD , Gilbert IH . 2022 . Repositioning of a diaminothiazole series confirmed to target the cyclin-dependent kinase CRK12 for use in the treatment of African animal trypanosomiasis . J Med Chem 65 : 5606 – 5624 . OpenUrl CrossRef PubMed (11). ↵ Giordani F , Paape D , Vincent IM , Pountain AW , Fernández-Cortés F , Rico E , Zhang N , Morrison LJ , Freund Y , Witty MJ , Peter R , Edwards DY , Wilkes JM , van der Hooft JJJ , Regnault C , Read KD , Horn D , Field MC , Barrett MP . 2020 . Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs . PLoS Pathog 16 : e1008932 . OpenUrl CrossRef PubMed (12). ↵ La Greca F , Magez S. 2011 . Vaccination against trypanosomiasis: can it be done or is the trypanosome truly the ultimate immune destroyer and escape artist? Hum Vaccin 7 : 1225 – 1233 . OpenUrl PubMed (13). ↵ Horn D. 2014 . Antigenic variation in African trypanosomes . Mol Biochem Parasitol 195 : 123 – 129 . OpenUrl CrossRef PubMed (14). ↵ Engstler M , Pfohl T , Herminghaus S , Boshart M , Wiegertjes G , Heddergott N , Overath P. 2007 . Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes . Cell 131 : 505 – 515 . OpenUrl CrossRef PubMed Web of Science (15). ↵ Radwanska M , Guirnalda P , De Trez C , Ryffel B , Black S , Magez S. 2008 . Trypanosomiasis-induced B cell apoptosis results in loss of protective anti-parasite antibody responses and abolishment of vaccine-induced memory responses . PLoS Pathog 4 : e1000078 . OpenUrl CrossRef PubMed (16). ↵ Bockstal V , Guirnalda P , Caljon G , Goenka R , Telfer JC , Frenkel D , Radwanska M , Magez S , Black SJ . 2011 . T . brucei infection reduces B lymphopoiesis in bone marrow and truncates compensatory splenic lymphopoiesis through transitional B-cell apoptosis. PLoS Pathog 7 : e1002089 . OpenUrl PubMed (17). ↵ Autheman D , Crosnier C , Clare S , Goulding DA , Brandt C , Harcourt K , Tolley C , Galaway F , Khushu M , Ong H , Romero-Ramirez A , Duffy CW , Jackson AP , Wright GJ . 2021 . An invariant Trypanosoma vivax vaccine antigen induces protective immunity . Nature doi: 10.1038/s41586-021-03597-x . OpenUrl CrossRef PubMed (18). ↵ Llewelyn MB , Hawkins RE , Russell SJ . 1992 . Discovery of antibodies . BMJ 305 : 1269 – 1272 . OpenUrl Abstract / FREE Full Text (19). ↵ Singh R , Chandley P , Rohatgi S. 2023 . Recent advances in the development of monoclonal antibodies and next-generation antibodies . ImmunoHorizons 7 : 886 – 897 . OpenUrl CrossRef PubMed (20). ↵ Pecetta S , Finco O , Seubert A. 2020 . Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era . Semin Immunol 50 : 101427 . OpenUrl PubMed (21). ↵ Taylor PC , Adams AC , Hufford MM , de la Torre I, Winthrop K , Gottlieb RL . 2021 . Neutralizing monoclonal antibodies for treatment of COVID-19 . Nat Rev Immunol 21 : 382 – 393 . OpenUrl CrossRef PubMed (22). ↵ Migone T-S , Subramanian GM , Zhong J , Healey LM , Corey A , Devalaraja M , Lo L , Ullrich S , Zimmerman J , Chen A , Lewis M , Meister G , Gillum K , Sanford D , Mott J , Bolmer SD . 2009 . Raxibacumab for the treatment of inhalational anthrax . N Engl J Med 361 : 135 – 144 . OpenUrl CrossRef PubMed Web of Science (23). ↵ Shepard HM , Phillips GL , D Thanos C , Feldmann M. 2017 . Developments in therapy with monoclonal antibodies and related proteins . Clin Med 17 : 220 – 232 . OpenUrl Abstract / FREE Full Text (24). ↵ Wilcox MH , Gerding DN , Poxton IR , Kelly C , Nathan R , Birch T , Cornely OA , Rahav G , Bouza E , Lee C , Jenkin G , Jensen W , Kim Y-S , Yoshida J , Gabryelski L , Pedley A , Eves K , Tipping R , Guris D , Kartsonis N , Dorr M-B , Modify I and MODIFY II Investigators . 2017 . Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection . N Engl J Med 376 : 305 – 317 . OpenUrl CrossRef PubMed (25). ↵ Gaudinski MR , Berkowitz NM , Idris AH , Coates EE , Holman LA , Mendoza F , Gordon IJ , Plummer SH , Trofymenko O , Hu Z , Campos Chagas A , O’Connell S , Basappa M , Douek N , Narpala SR , Barry CR , Widge AT , Hicks R , Awan SF , Wu RL , Hickman S , Wycuff D , Stein JA , Case C , Evans BP , Carlton K , Gall JG , Vazquez S , Flach B , Chen GL , Francica JR , Flynn BJ , Kisalu NK , Capparelli EV , McDermott A , Mascola JR , Ledgerwood JE , Seder RA , VRC 612 Study Team . 2021 . A monoclonal antibody for malaria prevention . N Engl J Med 385 : 803 – 814 . OpenUrl CrossRef PubMed (26). ↵ Kayentao K , Ongoiba A , Preston AC , Healy SA , Doumbo S , Doumtabe D , Traore A , Traore H , Djiguiba A , Li S , Peterson ME , Telscher S , Idris AH , Kisalu NK , Carlton K , Serebryannyy L , Narpala S , McDermott AB , Gaudinski M , Traore S , Cisse H , Keita M , Skinner J , Hu Z , Zéguimé A , Ouattara A , Doucoure M ‘bouye, Dolo A , Djimdé A , Traore B , Seder RA , Crompton PD , Mali Malaria mAb Trial Team . 2022 . Safety and efficacy of a monoclonal antibody against malaria in Mali . N Engl J Med 387 : 1833 – 1842 . OpenUrl CrossRef PubMed (27). ↵ MacGregor P , Gonzalez-Munoz AL , Jobe F , Taylor MC , Rust S , Sandercock AM , Macleod OJS , Van Bocxlaer K , Francisco AF , D’Hooge F , Tiberghien A , Barry CS , Howard P , Higgins MK , Vaughan TJ , Minter R , Carrington M. 2019 . A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis . PLoS Negl Trop Dis 13 : e0007373 . OpenUrl PubMed (28). ↵ Crosnier C , Staudt N , Wright GJ . 2010 . A rapid and scalable method for selecting recombinant mouse monoclonal antibodies . BMC Biol 8 : 76 . OpenUrl CrossRef PubMed (29). ↵ Jumper J , Evans R , Pritzel A , Green T , Figurnov M , Ronneberger O , Tunyasuvunakool K , Bates R , Žídek A , Potapenko A , Bridgland A , Meyer C , Kohl SAA , Ballard AJ , Cowie A , Romera-Paredes B , Nikolov S , Jain R , Adler J , Back T , Petersen S , Reiman D , Clancy E , Zielinski M , Steinegger M , Pacholska M , Berghammer T , Bodenstein S , Silver D , Vinyals O , Senior AW , Kavukcuoglu K , Kohli P , Hassabis D. 2021 . Highly accurate protein structure prediction with AlphaFold . Nature 596 : 583 – 589 . OpenUrl CrossRef PubMed (30). ↵ Abramson J , Adler J , Dunger J , Evans R , Green T , Pritzel A , Ronneberger O , Willmore L , Ballard AJ , Bambrick J , Bodenstein SW , Evans DA , Hung C-C , O’Neill M , Reiman D , Tunyasuvunakool K , Wu Z , Žemgulytė A , Arvaniti E , Beattie C , Bertolli O , Bridgland A , Cherepanov A , Congreve M , Cowen-Rivers AI , Cowie A , Figurnov M , Fuchs FB , Gladman H , Jain R , Khan YA , Low CMR , Perlin K , Potapenko A , Savy P , Singh S , Stecula A , Thillaisundaram A , Tong C , Yakneen S , Zhong ED , Zielinski M , Žídek A , Bapst V , Kohli P , Jaderberg M , Hassabis D , Jumper JM . 2024 . Accurate structure prediction of biomolecular interactions with AlphaFold 3 . Nature 630 : 493 – 500 . OpenUrl CrossRef PubMed (31). ↵ Murray M , Murray PK , McIntyre WIM . 1977 . An improved parasitological technique for the diagnosis of African trypanosomiasis . Transactions of the Royal Society of Tropical Medicine and Hygiene doi: 10.1016/0035-9203(77)90110-9 . OpenUrl CrossRef PubMed (32). ↵ Vieira P , Rajewsky K. 1988 . The half-lives of serum immunoglobulins in adult mice . Eur J Immunol 18 : 313 – 316 . OpenUrl CrossRef PubMed Web of Science (33). ↵ Ripoll JG , van Helmond N , Senefeld JW , Wiggins CC , Klassen SA , Baker SE , Larson KF , Murphy BM , Andersen KJ , Ford SK , Casadevall A , Joyner MJ . 2021 . Convalescent plasma for infectious diseases: Historical framework and use in COVID-19 . Clin Microbiol Newsl 43 : 23 – 32 . OpenUrl PubMed (34). Graham BS , Ambrosino DM . 2015 . History of passive antibody administration for prevention and treatment of infectious diseases . Curr Opin HIV AIDS 10 : 129 – 134 . OpenUrl CrossRef PubMed (35). ↵ Dias da Silva W , De Andrade SA , Megale ÂAA , De Souza DA , Sant’Anna OA , Magnoli FC , Guidolin FR , Godoi KS , Saladini LY , Spencer PJ , Portaro FCV . 2022 . Antibodies as snakebite antivenoms: Past and future . Toxins (Basel) 14 : 606 . OpenUrl PubMed (36). ↵ Talenti A , Powell J , Hemmink JD , Cook EAJ , Wragg D , Jayaraman S , Paxton E , Ezeasor C , Obishakin ET , Agusi ER , Tijjani A , Amanyire W , Muhanguzi D , Marshall K , Fisch A , Ferreira BR , Qasim A , Chaudhry U , Wiener P , Toye P , Morrison LJ , Connelley T , Prendergast JGD . 2022 . A cattle graph genome incorporating global breed diversity . Nat Commun 13 : 910 . OpenUrl PubMed (37). ↵ Chen C , Garcia Z , Chen D , Liu H , Trelstad P. 2025 . Cost and supply considerations for antibody therapeutics . MAbs 17 : 2451789 . OpenUrl CrossRef PubMed (38). ↵ Zenonos ZA , Dummler SK , Müller-Sienerth N , Chen J , Preiser PR , Rayner JC , Wright GJ . 2015 . Basigin is a druggable target for host-oriented antimalarial interventions . J Exp Med 212 : 1145 – 1151 . OpenUrl Abstract / FREE Full Text (39). Longoni SS , Tiberti N , Bisoffi Z , Piubelli C. 2021 . Monoclonal antibodies for protozoan infections: A future reality or a utopic idea? Front Med (Lausanne) 8 : 745665 . OpenUrl PubMed (40). ↵ Sparrow E , Friede M , Sheikh M , Torvaldsen S. 2017 . Therapeutic antibodies for infectious diseases . Bull World Health Organ 95 : 235 – 237 . OpenUrl CrossRef PubMed (41). ↵ Corless E , Hao Y , Jia H , Kongsuphol P , Tay DMY , Ng SY , Sikes HD . 2022 . Generation of thermally stable affinity pairs for sensitive, specific immunoassays . Methods Mol Biol 2491 : 417 – 469 . OpenUrl PubMed (42). ↵ Boschek CB , Apiyo DO , Soares TA , Engelmann HE , Pefaur NB , Straatsma TP , Baird CL . 2009 . Engineering an ultra-stable affinity reagent based on Top7 . Protein Eng Des Sel 22 : 325 – 332 . OpenUrl CrossRef PubMed (43). ↵ De Trez C , Khan S , Magez S. 2020 . T . brucei infections abrogate diverse plasma cell-mediated effector B cell responses, independently of their specificity, affinity and host genetic background. PLoS Negl Trop Dis 14 : e0008358 . OpenUrl PubMed (44). ↵ Pyzik M , Kozicky LK , Gandhi AK , Blumberg RS . 2023 . The therapeutic age of the neonatal Fc receptor . Nat Rev Immunol 23 : 415 – 432 . OpenUrl CrossRef PubMed (45). ↵ Foss S , Sakya SA , Aguinagalde L , Lustig M , Shaughnessy J , Cruz AR , Scheepmaker L , Mathiesen L , Ruso-Julve F , Anthi AK , Gjølberg TT , Mester S , Bern M , Evers M , Bratlie DB , Michaelsen TE , Schlothauer T , Sok D , Bhattacharya J , Leusen J , Valerius T , Ram S , Rooijakkers SHM , Sandlie I , Andersen JT . 2024 . Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria . Nat Commun 15 : 2007 . OpenUrl CrossRef PubMed (46). ↵ Mackness BC , Jaworski JA , Boudanova E , Park A , Valente D , Mauriac C , Pasquier O , Schmidt T , Kabiri M , Kandira A , Radošević K , Qiu H. 2019 . Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life . MAbs 11 : 1276 – 1288 . OpenUrl CrossRef PubMed (47). ↵ Noble A , Paudyal B , Schwartz JC , Mwangi W , Munir D , Tchilian E , Hammond JA , Graham SP . 2023 . Distinct effector functions mediated by Fc regions of bovine IgG subclasses and their interaction with Fc gamma receptors . Front Immunol 14 . (48). ↵ Galaway F , Yu R , Constantinou A , Prugnolle F , Wright GJ . 2019 . Resurrection of the ancestral RH5 invasion ligand provides a molecular explanation for the origin of P . falciparum malaria in humans. PLoS Biol 17 : e3000490 . OpenUrl PubMed View the discussion thread. Back to top Previous Next Posted July 08, 2025. Download PDF Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX Delphine Autheman , Cristina Viola , Georgina Rhodes , Simon Clare , Cordelia Brandt , Katherine Harcourt , Gavin J. Wright bioRxiv 2025.07.08.663690; doi: https://doi.org/10.1101/2025.07.08.663690 Share This Article: Copy Citation Tools Cure of experimental Trypanosoma vivax infection with a single dose of an unmodified antibody-based drug targeting the invariant flagellum cell surface protein IFX Delphine Autheman , Cristina Viola , Georgina Rhodes , Simon Clare , Cordelia Brandt , Katherine Harcourt , Gavin J. Wright bioRxiv 2025.07.08.663690; doi: https://doi.org/10.1101/2025.07.08.663690 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Microbiology Subject Areas All Articles Animal Behavior and Cognition (7642) Biochemistry (17715) Bioengineering (13907) Bioinformatics (42003) Biophysics (21470) Cancer Biology (18624) Cell Biology (25533) Clinical Trials (138) Developmental Biology (13390) Ecology (19935) Epidemiology (2067) Evolutionary Biology (24356) Genetics (15617) Genomics (22529) Immunology (17753) Microbiology (40432) Molecular Biology (17200) Neuroscience (88681) Paleontology (667) Pathology (2840) Pharmacology and Toxicology (4828) Physiology (7653) Plant Biology (15161) Scientific Communication and Education (2046) Synthetic Biology (4304) Systems Biology (9826) Zoology (2271)